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Background/purpose: Oral lichen planus (OLP) is the most frequent oral lesion 
found in patients with hepatitis C virus (HCV) infection. The aims of this study 
were to investigate the prevalence of OLP among chronic hepatitis C patients, to 
clarify the role of HCV in the pathogenesis of OLP, and to assess its relationship to 
transaminase levels.
Materials and methods: Two groups of subjects were studied; 277 hepatitis C patients 
were examined for OLP (Group 1) and 5273 outpatients seeking dental care within 
1 year were used as a control (Group 2) to determine the prevalence of OLP in 
the general population. The dental and hepatic records were collected and analyzed.
Results: The prevalences of OLP were 4.7% (n = 13) in Group 1 and 2.0% (n = 104) in 
Group 2 and significantly differed (P = 0.002). All 13 OLP cases occurred in hepatitis C 
patients who had experienced elevated alanine transaminase levels of > 80 IU/L 
within the 2 previous years, regardless of whether they were treated with interfer-
on-ribavirin combination therapy or not. There was a strong association between 
elevated transaminase levels and the development of HCV-related OLP lesions 
(P = 0.014). Of the 13 OLP patients, two were in the group with a sustained virologic 
response (SVR) to HCV therapy, two were in the group without an SVR, and nine 
were in the non-therapy group. The incidence of OLP in hepatitis C patients did not 
significantly differ between those who showed an SVR to HCV therapy and those 
who did not respond or did not receive therapy (P = 0.560).
Conclusion: We concluded that: (1) elevation of transaminase levels is associated 
with the detection of HCV-related OLP, and (2) HCV-related OLP can remain 
unchanged for years after an SVR to HCV therapy. The findings revealed that the 
role of HCV in OLP pathogenesis is due to host factors induced by HCV rather than a 
direct cytopathic effect of HCV.
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Introduction
Oral lichen planus (OLP) is frequently seen in pa-
tients with chronic hepatitis C virus (HCV) infection 
and was reported to be an extrahepatic manifesta-
tion of HCV.1−3 Many studies associated OLP with 
HCV, especially in HCV-endemic areas such as 
southern Europe and Japan, although the mecha-
nisms of HCV in OLP pathogenesis are unclear.1,4−9
HCV RNA was detected in the saliva and oral mu-
cosa of patients with chronic hepatitis C. Persistent 
HCV infection of the oral epithelium may trigger a 
host immune response and result in HCV-related 
OLP. However, the underlying mechanism remains 
unclear.1,9−11 Chung et al.12 found that elevation of 
transaminase levels significantly increased the risk 
of atrophic-erosive OLP, particularly in HCV pa-
tients. Ali and Suresh13 reported a strong associa-
tion between elevated transaminase levels and 
detection of erosive OLP, but no correlation be-
tween OLP and HCV infection was determined in 
their study. Nagao et al.8,14 observed HCV-related 
OLP in patients with severe liver dysfunction and 
also in patients without it. Further, there were no 
significant differences in serum HCV RNA levels and 
HCV genotypes between the HCV with OLP group 
and the HCV without OLP group. Arrieta et al.15 
detected HCV replicates in epithelial cells of anti-
HCV-positive patients with and without OLP. Those 
reports suggest that host factors induced by HCV 
infection are more important than viral factors in 
the pathogenesis of HCV-related OLP.
Combination therapy with interferon (IFN) and 
ribavirin is the current standard treatment for 
chronic HCV infections. Some reported the therapeu-
tic effects of IFN on OLP lesions, but others reported 
that OLP can be aggravated or triggered by IFN.16,17
There is no report describing the therapeutic ef-
fect of IFN and ribavirin for HCV-related OLP in 
chronic hepatitis C patients. Also, controversy and 
uncertainty regarding the association of the activity 
of HCV in OLP led us to conduct this study. The aims 
of this study were to investigate the prevalence of 
OLP among patients with chronic hepatitis C in 
southern Taiwan, to clarify the role of HCV in the 
pathogenesis of OLP by investigating the progression 
and occurrence of OLP in HCV patients treated with 
IFN plus ribavirin, and to assess the possible asso-
ciation of transaminase levels in OLP. We conducted 
oral examinations of chronic hepatitis C patients 
with the investigators blinded to their HCV status.
Material and methods
Two hundred and seventy-seven consecutive pa-
tients (152 women and 125 men), aged 34−87 years 
(mean, 60.5 ± 10.7 years) with a diagnosis of 
chronic HCV infection and who had been followed 
up for at least 2 years at the Division of Hepato-
Gastroenterology of Kaohsiung Chang Gung 
Memorial Hospital, were examined for OLP (Group 
1), and 5273 outpatients seeking dental treatment 
at the Department of Oral Pathology and Family 
Dentistry within 1 year were used as the control 
group (Group 2) to determine the prevalence of 
OLP in the general population. All patients enrolled 
in the study came from the same general popula-
tion in southern Taiwan. With the investigators 
blinded to a patient’s medical history including 
his/her HCV status and whether he/she had re-
ceived HCV treatment, OLP was observed through 
a clinical examination by a well-trained family 
dentist, and then double-checked by an oral medi-
cine specialist. The study was conducted from 
August 2007 to March 2009. A diagnosis of OLP was 
made on the basis of the recognized typical clini-
cal features; in suspicious cases, a diagnosis was 
confirmed by a biopsy. Reticular OLP was defined 
by the presence of a lace-like network of grayish-
white lines (Wickham’s striae). Atrophic, erosive 
and bullous types of OLP lesions were accepted as 
a subtype only in the presence of reticular OLP 
elsewhere.18−20 Participants were divided into a 
reticular OLP group and an atrophic-erosive OLP 
group according to the clinical type of lesions ob-
served. Patients suspected of graft-to-host dis-
ease, or areca nut use or drug-induced lichenoid 
eruptions were excluded. Demographic data such 
as age, sex, past medical history, type of OLP le-
sion, and its duration were collected using a check-
list after receiving a patient’s consent.
HCV infection was diagnosed by detecting anti-
bodies against HCV (anti-HCV, with microparticle 
enzyme immunoassay (AxSYM HCV version 3.0; 
Abbott Diagnostics, Chicago, IL, USA). HCV RNA by 
qualitative polymerase chain reaction (COBAS 
AMPLICOR HCV test version 2.0; Roche Diagnostics, 
Basel, Switzerland; with a lower limit of detection 
of 50 IU/mL) was detected when needed. Liver 
function tests including serum aspartate ami-
notransferase (AST) and alanine aminotransferase 
(ALT) levels were measured, and serum AST and 
ALT levels of < 40 IU/L were assumed to be normal. 
AST and ALT levels were estimated in all cases in 
Group 1 from several weeks to several months. A 
sustained virologic response (SVR) was defined by 
the absence of HCV RNA at 24 weeks after comple-
tion of HCV therapy. The goal of treatment for 
chronic HCV infection is an SVR accompanied by 
improvement in the liver damage. In this study, a 
therapeutic response was judged after IFN-ribavirin 
combination therapy to be a complete responder if 
there was an SVR with normalization of serum ALT 
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levels, and an incomplete responder if there was 
neither an SVR nor a return to normal transami-
nase levels. The incidences of OLP in the hepatitis 
C patients (Group 1) were compared between 
those with elevated transaminase levels of > 80 IU/L 
(double the normal limits of the value of ALT) and 
those whose ALT levels never exceeded 80 IU/L and 
between those who showed an SVR to HCV therapy 
and those who did not respond (non-SVR) or did 
not receive therapy. An ultrasonographic scoring 
system consisting of the liver surface, parenchyma, 
vascular structure and splenic size was used to de-
scribe the severity of hepatic parenchymal dam-
age.21 In the scoring system, a score of 4 indicates 
a normal situation, scores of 5−7 indicate hepatic 
fibrosis, a score of 8 indicates early cirrhosis, and 
scores of 9 and higher indicate cirrhosis. The in-
traobserver reproducibility of our gastroenterolo-
gist was documented.22 In this study, we defined 
scores of 4−6 as normal or mild hepatic fibrosis, 
while scores of 7 and higher were defined as defi-
nite and advanced hepatic fibrosis. The ultrasono-
graphic evaluation of 277 HCV patients by this 
scoring system was used to investigate the correla-
tion between the prevalence of OLP and the de-
gree of liver abnormalities.
All collected data were analyzed by the compu-
ter package SPSS version 15.0 software (SPSS, 
Chicago, IL, USA). Chi-squared and Fisher’s exact 
tests were used to analyze the association between 
qualitative variables. In all analyses, P < 0.05 was 
considered statistically significant. The study was 
approved by the institutional review board of 
Chang Gung Memorial Hospital.
Results
OLP was the most prevalent oral lesion in hepati-
tis C patients (Group 1) with 13 cases (9 females 
and 4 males, 4.7%; Table 1). The remaining lesions 
consisted of leukoplakia in five cases (1.8%), aph-
thous stomatitis in three (1.1%), oral candidosis in 
two (0.7%), and cheilitis in two (0.7%) (Table 2). 
No abnormalities of the oral mucosa were found in 
the remaining 252 cases (91.0%). In the 13 HCV-
related OLP patients, the painless reticular form 
of OLP was the most common oral lesion (n = 10, 
76.9%); only three showed atrophic-erosive OLP 
(23.1%), with the buccal mucosa being the most-
often affected site. On the contrary, of the 104 
OLP patients in Group 2, the most prevalent OLP 
lesion was the painful erosive type (n = 90, 86.5%) 
and 14 patients (13.5%) showed reticular OLP. The 
clinical features of OLP between HCV patients 
(Group 1) and dental outpatients (Group 2) statis-
tically differed (P < 0.0001).
The prevalences of OLP were 4.7% in Group 1 
and 2.0% in Group 2 with a significant difference 
(P = 0.002). In total, 125 hepatitis C patients com-
pleted HCV therapy with IFN or peginterferon and 
ribavirin; 83 (66.4%) of them showed an SVR with a 
return to normal ALT levels, and 42 patients (33.6%) 
showed a non-SVR with elevated ALT levels. 
Because the hepatitis C status did not reach the 
therapeutic requirements of health insurance of 
Taiwan (a persistent ALT level of > 80 IU/L and sig-
nificant hepatic fibrosis), adverse effects from 
IFN, or financial problems, the other 152 hepatitis 
C patients did not receive HCV therapy or failed to 
complete therapy. Of the 13 HCV-related OLP pa-
tients, nine were in the non-therapy group (69.2%), 
two were in the non-SVR group (15.4%), and two 
were in the SVR group (15.4%). The OLP prevalence 
in the SVR group (n = 2, 2.4%) was lower than that 
of the non-SVR group plus the non-therapy group 
(n = 11, 5.7%). However, no significant difference 
was found (P = 0.240; Table 3). The HCV-related 
OLP in two patients developed before HCV therapy 
and persisted after an SVR to therapy for several 
months to 1 year. All 13 OLP patients were hepati-
tis C patients who had experienced elevated ALT 
Table 1. Age and sex distribution of 277 hepatitis 
C patients with oral lichen planus (OLP) lesions in 
Group 1
 Patients with OLP
 Male Female Total
Age (yr)
 30−39 0/6 1/5 1/11
 40−49 0/15 0/15 0/30
 50−59 2/38 2/52 4/90
 ≥ 60 2/66 6/80 8/146
Total 4/125 9/152 13/277 (4.7%)
Table 2. Distribution of oral mucosal lesions in 277 
hepatitis C patients (Group 1)
Oral mucosa condition n (%)
Oral lichen planus 13 (4.7)
Leukoplakia 5 (1.8)
Aphthous ulcers 3 (1.1)
Oral candidosis 2 (0.7)
Cheilitis 2 (0.7)
Normal mucosa 252 (91.0)
Total 277 (100)
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Table 3. Prevalence of oral lichen planus (OLP) in 
hepatitis C virus (HCV) patients (Group 1), stratified 
by a sustained virologic response (SVR) to HCV ther-
apy with interferon and ribavirin and non-SVR to 
therapy plus the non-therapy group*†
 OLP (−) OLP (+)‡ Total
SVR 81 (29.2) 2§ (0.7) 83 (30.0)
Others 183 (66.1) 11 (4.0) 194 (70.0)
Total 264 (95.3) 13 (4.7) 277 (100)
*Data are presented as n (%); †percentages may not add up to 
total because of rounding; ‡not significant (P = 0.240); §2.4% 
(2/83) with an SVR; 5.7% (11/194) with a non-SVR and no 
therapy.
Table 4. Prevalence of oral lichen planus (OLP) in 
hepatitis C virus (HCV) patients (Group 1), stratified 
by alanine transaminase (ALT) levels of > 80 IU/L 
within 2 years of follow-up, by whether they were 
treated with HCV therapy or not*
 OLP (−) OLP (+)† Total
ALT
 < 80 IU/L 85 (30.7) 0‡ (0) 85 (30.7)
 > 80 IU/L 179 (64.6) 13§ (4.7) 192 (69.3)
Total 264 (95.3) 13§ (4.7) 277 (100)
*Data are presented as n (%); †significant (P = 0.014); 
‡0% (0/13) with OLP; §100% (13/13) with OLP.
levels of > 80 IU/L within the past 2 years, regard-
less of whether they were treated with HCV ther-
apy or not. Elevated transaminase levels of > 80 IU/L 
were significantly related to the development of 
OLP (P = 0.014; Table 4).
Ultrasonographic scores of 7−9 indicating defi-
nite to advanced hepatic fibrosis were detected in 
eight of 13 HCV-related OLP patients, and scores 
of 4−6 indicating normal to mild hepatic fibrosis 
were found in the other five HCV-related OLP pa-
tients. When possible differences in OLP preva-
lence with respect to the degree of liver damage 
by the ultrasonographic scoring system between 
the advanced hepatic fibrosis group and the nor-
mal to mild hepatic fibrosis group were investi-
gated, a significant difference between the groups 
was not found (P = 0.566; Table 5).
Discussion
According to our study, the prevalence of OLP in 
southern Taiwanese patients with hepatitis C was 
4.7%. This was significantly higher than the preva-
lence of OLP in the general population (2.0%), 
which was used as a control in our study (P = 0.002). 
The prevalence of OLP in 277 hepatitis C patients 
(4.7%) was quite similar to the results of other au-
thors, such as Figueiredo et al.23 who reported a 
4.7% incidence of OLP among 126 patients with 
HCV infection in Brazil, Nagao et al.24 who re-
ported a 4.8% incidence of OLP among 84 patients 
with HCV infection in Japan, and Pawlotsky et al.25 
who reported a 5% incidence of OLP among 61 pa-
tients with HCV infection in France. To avoid inves-
tigator bias, the two investigators who investigated 
all of the HCV patients were blinded to their hepa-
titis C activity. If patients with known HCV therapy 
or transaminase levels were more likely to be over-
diagnosed or underdiagnosed with OLP, this would 
have resulted in arbitrary statistics. We did not 
find a higher OLP prevalence in hepatitis C patients 
treated with IFN and ribavirin, in contrast to re-
ports of OLP being triggered or aggravated by IFN 
Table 5. Prevalence of oral lichen planus (OLP) in hepatitis C virus (HCV) patients (Group 1), stratified by the 
ultrasonographic scoring system*
 OLP (−) OLP (+)† Total
Echo score
 4−6 (normal or mild hepatic fibrosis) 123 (44.4) 5‡ (1.8) 128 (46.2)
 7−9 (definite or advanced hepatic fibrosis) 141 (50.9) 8§ (2.9) 149 (53.8)
Total 264 (95.3) 13 (4.7) 277 (100)
*Data are presented as n (%); †not significant (P = 0.566); ‡38.5% (5/13) with OLP; §61.5% (8/13) with OLP.
by other authors.16,26−28 Furthermore, HCV-related 
OLP was observed to be more common in the non-
therapy group (69.2%) than in the IFN-ribavirin 
combination therapy group (30.8%). However there 
was no significant difference (P = 0.287). To our 
knowledge, this is the first report to investigate 
the prevalence of OLP among chronic hepatitis C 
patients in southern Taiwan, and it describes the 
effect of IFN-ribavirin combination therapy for 
chronic hepatitis C patients with HCV-related OLP.
Among 13 HCV-related OLP cases, the reticular 
form of OLP (76.9%) was the most prevalent oral 
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lesion in hepatitis C patients. This is compatible 
with the finding of Mignogna et al.29 that the re-
ticular form is more frequent in HCV-positive pa-
tients than in HCV-negative patients. Most hepatitis 
C patients with reticular OLP do not seek treat-
ment because of the asymptomatic nature of the 
disease. Variations in OLP symptoms between HCV 
patients (Group 1) and dental outpatients (Group 
2) may have influenced the option of seeing doc-
tors and resulted in the different manifestations of 
OLP between the two groups. All HCV-related OLP 
cases among the 13 hepatitis C patients were tol-
erable. No patient subjectively complained about 
gross or symptomatic changes, regardless of 
whether they were treated with IFN-ribavirin com-
bination therapy or not. Three atrophic-erosive 
OLP and two reticular OLP patients were referred 
to the dental department of the same hospital for 
treatment, and showed dramatic remission of signs 
and symptoms with levamisole and low-dose pred-
nisolone therapy within 2 weeks, and there was no 
evidence of erosive OLP after 4−6 weeks of treat-
ment. The HCV-related OLP in two cases developed 
before HCV therapy and remained unchanged after 
an SVR to therapy. Nevertheless, HCV-related OLP 
responded to conventional therapy for OLP as 
well.30 The beneficial effects of prednisolone plus 
levamisole on HCV-related OLP also suggest immu-
nopathogenesis.30 The etiology of OLP is thought 
to reflect a cell-mediated immune response, al-
though the mechanisms remain to be addressed.31−33 
Leukoplakia was the second most common lesion 
in hepatitis C patients. Caution should be taken to 
regularly follow up on the leukoplakia, as with OLP, 
for possible malignant changes.1
IFN with antiviral, antiproliferative and immu-
nomodulatory functions is effective in treating 
chronic hepatitis C. The rate of response to IFN is 
enhanced by increasing the IFN dose and extend-
ing the treatment duration. The addition of ribavi-
rin to IFN therapy increases the SVR rate in 
Taiwanese HCV patients by up to approximately 
60%.34−37 In this study, the SVR rate to IFN-ribavirin 
combination therapy was 66.4%. The long-term 
benefits of SVR are decreased infectivity, lower 
risks of developing cirrhosis and hepatocellular 
carcinoma (HCC), and an improved quality of life. 
Therapeutic effects of IFN and ribavirin have been 
confirmed in extrahepatic lesions other than 
OLP.38−40 We found that HCV-related OLP in chronic 
hepatitis C patients with SVR to IFN-ribavirin com-
bination therapy can be persistent. As OLP neither 
disappeared nor improved but remained unchanged 
when HCV RNA became negative after HCV ther-
apy, it is unlikely that HCV directly participates in 
the pathogenesis of OLP lesions. Our data suggest 
that HCV is not sufficient in itself to be a causative 
agent for the development of OLP lesions, and that 
host factors play important roles in the pathogen-
esis of HCV-related OLP. This was supported by 
other researchers who reported that the percent-
ages of HCV-infected oral mucosa cells do not cor-
relate with serum viremia levels or the intensity of 
inflammatory infiltrates in OLP lesions, together 
with the fact that HCV RNA levels or HCV geno-
types in HCV patients with or without OLP did not 
significantly differ.14,15,41 Furthermore, Femiano 
and Scully42 found that an increase in immunomod-
ulatory cytokines in HCV-positive OLP lesions in-
duced cell-mediated cytotoxicity to basal layer 
cells and resulted in OLP lesions. Pilli et al.43 dem-
onstrated that HCV-specific CD4+ and CD8+ T cells 
were present within intralesional infiltrates in 
HCV-positive OLP lesions, thus providing strong ev-
idence for the involvement of HCV in the patho-
genesis of OLP. Although it is unclear how HCV 
affects the immune system of hosts, it is thought 
that the host immune system plays an important 
role in the development of HCV-related OLP. For 
further elucidation of the therapeutic effects of 
IFN-ribavirin combination therapy on HCV-related 
OLP, an accumulation of more cases and long-term 
follow-up are needed. Also in this study, nine of 13 
HCV-related OLP patients were female; therefore, 
sex may be related to the occurrence of OLP.
Chronic hepatitis C has peaks and valleys of ac-
tivity, so most hepatitis C patients have ALT levels 
that may go up and down or remain stable over 
time. No HCV-related OLP was found in hepatitis C 
patients whose ALT levels were always < 80 IU/L 
during 2 years of follow-up, regardless of whether 
or not they were treated with HCV therapy. Such a 
finding is quite interesting and corresponds to 
some earlier reports that there is a close associa-
tion between transaminase elevation and the de-
velopment of HCV-related OLP lesions,8,12,13 
although no definite values of elevated ALTs were 
mentioned in those reports. As far as we know, 
these ALT numbers do not have a linear relation-
ship with the stage of liver damage in HCV infec-
tion. A level of ALT of 160 IU/L is not twice as bad 
as 80 IU/L, and an ALT value of 95 IU/L and 80 IU/L 
are essentially the same to a liver specialist. It is 
not surprising to find that there were no signifi-
cant differences in OLP prevalence between the 
advanced hepatic fibrosis group and the normal to 
mild hepatic fibrosis group according to the ultra-
sonographic evaluation (P = 0.566) in the study. 
However, the prevalence of OLP in the advanced 
hepatic fibrosis group was higher than that of the 
normal to mild hepatic fibrosis group. Therefore, 
further studies are needed to clarify the mecha-
nism of this association between ALT levels 
of > 80 IU/L and the detection of HCV-related OLP.
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In conclusion, our data show that among HCV 
patients, the rate of OLP is twofold higher (4.7% 
vs. 2.0% in the general population); and among 
OLP patients the rate of HCV infection is 11-fold 
higher (22.1% vs. 2.0% in control subjects of our 
previous study). We concluded that at least in 
southern Taiwan, there is a positive association 
between HCV and OLP and a strong association be-
tween elevated transaminase levels of > 80 IU/L 
and the detection of HCV-related OLP. Physicians 
should be aware that OLP can occur or persist even 
when serum HCV RNA is negative after IFN-ribavirin 
combination therapy for hepatitis C patients. 
These findings contradict the notion that HCV is 
the direct causal agent of OLP. In other words, HCV 
together with other factors (either viral or host-
related immune responses) may be responsible for 
some cases of HCV-related OLP.
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